ALLMedicine™ Antinuclear Antibody Center
Research & Reviews 682 results
BMC Musculoskeletal Disorders; Lin C, Shen J et. al.
Nov 25th, 2022 - Systemic sclerosis (SSc) is an incurable autoimmune disease characterized by progressive skin fibrosis and organ failure. Tenosynovitis is a common musculoskeletal manifestation, but tendon rupture has seldom reported in SSc. We present a rare cas...
Journal of the European Academy of Dermatology and Venere... Jindal AK, Handa S et. al.
Nov 23rd, 2022 - Juvenile localized scleroderma or morphea, a rare chronic autoimmune disease predominantly affects skin, subcutaneous tissue, and occasionally the adjacent muscle, fascia, and bone. We report the largest single centre cohort of patients with JLS f...
BMC Pediatrics; Liu C, Jin Y et. al.
Nov 23rd, 2022 - Kikuchi-Fujimoto disease (KFD) is a self-limiting and benign disease characterized by cervical lymphadenopathy and fever. Although KFD should be made differentially diagnosed from infectious, autoimmune, and malignant diseases, it sometimes occurs...
Clinical Journal of Gastroenterology; Takakusagi S, Takagi H et. al.
Nov 21st, 2022 - A woman in her late 70 s was diagnosed with liver injury at a health examination. Despite treatment with ursodeoxycholic acid at a nearby hospital, her transaminase levels elevated in two peaks. She was transferred to our hospital 77 days after th...
European Journal of Ophthalmology; Kara M, Ozdemir GN et. al.
Nov 9th, 2022 - Cat-scratch disease (CSD) is a systemic bacterial infection caused by Bartonella henselae. The disease is typically characterized by regional lymphadenopathy developing after scratches from domestic or feral cats. Rarely, systemic involvement may ...
Drugs 11 results see all →
Clinicaltrials.gov 14 results
Oct 10th, 2022 - Eligible patients received vaccinations consisting of the NY-ESO-1 protein (100 µg) combined with CpG 7909 (2.5 mg) administered intradermally every 3 weeks for 4 doses. Patients who demonstrated stable disease, minor response, partial response, o...
Jul 19th, 2022 - This prospective, open-label, single-center, one-arm clinical trial aims at evaluating the efficacy and safety of avatrombopag in Chinese adult ITP patients with autoantibodies fail (due to intolerance or resistance) to eltrombopag or herombopag t...
Jun 23rd, 2022 - The reason for this study is to see if the study drug baricitinib given orally is safe and effective in participants with active juvenile idiopathic arthritis (JIA)-associated uveitis or chronic anterior antinuclear antibody-positive uveitis from ...
May 26th, 2022 - Study KD025-206 was a phase 2, open-label, dose-finding, safety, tolerability, activity, and PK study of KD025 in subjects with psoriasis who had failed at least 1 line of systemic therapy or phototherapy. Subjects received KD025 PO for 12 weeks. ...
May 11th, 2022 - This is a prospective, open-label, nonrandomized, multicenter clinical trial aiming at comparing the efficacy and safety of combined use of eltrombopag with low-dose rituximab vs. the best available therapy（BAT）in adult immune thrombocytopenia (...
News 174 results
Sep 19th, 2022 - The diagnosis for this case is psoriatic arthritis (PsA). The 2018 American College of Rheumatology/National Psoriasis Foundation guidelines offer current treatment recommendations for this condition.
Catherine Grace P. Hobayan, BS, Madison Grinnell, MD et. al.
Aug 31st, 2022 - The Diagnosis: Scleromyxedema A punch biopsy of the upper back performed at an outside institution revealed increased histiocytes and abundant interstitial mucin confined to the papillary dermis (Figures 1 and 2), consistent with the lichen myxede.
Timothy J. Zimmerman, MD, Saira J. George, MD
Aug 24th, 2022 - To the Editor: Dermatofibromas (also known as fibrous histiocytomas) are benign fibrous nodules that most often arise as solitary lesions on the lower extremities. Multiple eruptive dermatofibromas (MEDFs) are uncommon and have been defined as mor.
David Walton Crasto Jr, DO, Loren Touma, DO et. al.
Jun 28th, 2022 - To the Editor: Tumor necrosis factor α (TNF-α) inhibitor–induced lupuslike syndrome (TAILS) is a newly described entity that refers to the onset of subacute cutaneous lupus erythematosus (SCLE) during drug therapy with TNF-α antagonists. The condi.
Jun 17th, 2022 - The Food and Drug Administration has approved a new diagnostic blood test to detect monospecific Ribosomal P antibodies to support a diagnosis of systemic lupus erythematosus (SLE), particularly for people who are antinuclear antibody-negative, ac...